the aim of the study is to describe the management and outcome of patients having an osteo-articular infection treated by tedizolid as a suppressive antibiotic therapy.
Study Type
OBSERVATIONAL
Enrollment
17
description of osteo-articular infection managed with tedizolid as a suppressive antibiotic therapy
Hospices Civils de Lyon
Lyon, France
rate of patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic therapy
proportion of patients having tedizolid as a suppressive antibiotic therapy
Time frame: between 2016 and 2021
rate of failure in patients having had a BJI/PJI treated with tedizolid as a suppressive antibiotic
proportion of patients having a failure under tedizolid as a suppressive antibiotic therapy
Time frame: 2 years
rate of adverse event in patients having had a BJI/PJI treated with tedizolid as a suppressive
proportion of patients having a adverse event under tedizolid as a suppressive antibiotic therapy
Time frame: through study completion, an average of 1 year
Description of patients having had a BJI/PJI treated with tedizolid as a suppressive
type of patients: age, CMI, comorbidities...
Time frame: 2 years
Description of BJI/PJI treated with tedizolid as a suppressive
implant or prothese or not, acute/ chronic, bacteriology
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.